V

Voyager Therapeutics
D

VYGR

5.76000
USD
0.06
(1.05%)
Market Closed
Volume
9,190
EPS
-1
Div Yield
-
P/E
9
Market Cap
314,643,375
OverviewSignalsIdeasNews
Related Instruments
    A
    ALKS
    -0.220
    (-0.73%)
    29.750 USD
    A
    ARCT
    0.680
    (4.59%)
    15.500 USD
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CLLS
    0.00000
    (0.00%)
    1.58000 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    Q
    QURE
    1.550
    (10.00%)
    17.050 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    More
News

Title: Voyager Therapeutics

Sector: Healthcare
Industry: Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.